Health
Sanofi and GSK start Phase II study of their COVID-19 vaccine candidate – European Pharmaceutical Review
The dose finding study will assess the safety, reactogenicity and immunogenicity of the investigational COVID-19 vaccine in 720 participants.
Posted: 24 February 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies investigational COVID-19 vaccine in 720 participants.
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study of their adjuvanted recombinant protein COVID-19 vaccine candidate.
The Phase II trial is a randomised, double-blind, multi-centre dose finding study and will evaluate…
-
Noosa News24 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General20 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General13 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General23 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity